IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection. Review uri icon

Overview

abstract

  • IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8+ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.

publication date

  • July 9, 2020

Research

keywords

  • Interleukin-15
  • Neoplasms

Identity

PubMed Central ID

  • PMC7466855

Scopus Document Identifier

  • 85087809225

Digital Object Identifier (DOI)

  • 10.1016/j.immuni.2013.07.012

PubMed ID

  • 32934886

Additional Document Info

volume

  • 9

issue

  • 1